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Successful PDGFR-a/b
targeting with imatinib in uterine
sarcoma
Uterine sarcomas are a heterogeneous group of neoplasms
with a propensity for metastasis and resistance to
conventional therapy and represent 8% of all uterine
malignancies. They consist of pure stromal tumors, the
endometrial stromal sarcomas (ESSs) and leiomyosarcomas,
mixed epithelial and mesenchymal tumors and
carcinosarcomas [1]. The poor prognosis of uterine sarcomas
is due, in part, to the limited success of treatments meant to
enhance local and distant disease control after surgical
resection. Response to chemotherapy in these cases is
limited, and while radiotherapy may decrease local disease
recurrence, its use has not affected overall survival [2]. The
aggressive nature of uterine sarcomas and the failure of
conventional therapy highlight the need for new treatment
strategies, which in turn result in selective inhibition of tumor
cell growth and the initiation of apoptosis [3]. Here, we
describe a patient with relapsed ESS who, in the lack of other
applicable therapies, was explored for KIT and platelet-
derived growth factor receptor (PDGFR)-a/b expression and
who responded significantly to treatment with imatinib
mesylate.
This 75-year-old woman was admitted in October 2008 to
our hospital for vaginal bleeding and discharge as well as
discomfort in the lower pelvis. Eight years earlier, the patient
had undergone vaginal hysterectomy because of low-grade ESS.
In 2004, a tumor mass in the right ovary was resected and
a singular metastasis of the previously diagnosed ESS found.
This time postoperative local transcutaneous radiotherapy was
carried out (32 Gy).
At admission in 2008, a moderate microcytic anemia
(hemoglobin level 11.4 g/dl) with low ferritin level 11 lg/l
(10–200 lg/l) was noted. Leukocyte and thrombocyte counts as
well as liver tests and renal function were within normal
range. A computed tomography (CT) scan revealed recurrence
of a mass measuring 14 · 9 cm2 in the lower pelvis with
suspected infiltration of the urinary bladder (Figure 1).
A biopsy was taken. Histological work-up confirmed relapse of
the low-grade ESS according to the World Health Organization
criteria.
Facing this relapse after two surgeries and irradiation, we
searched for treatment options and carried out
immunohistologic staining for tyrosine kinase receptors KIT,
PDGFR-a and -b as described before [4].
Both PDGFR-b and PDGFR-a were strongly expressed in the
tissue specimen, whereas KIT stained negative (figure not
shown). We have determined these receptors as a number
of tyrosine kinase inhibitors, such as imatinib, are in
widespread clinical use. Imatinib is an inhibitor of bcr-abl, KIT
and PDGFR and has revolutionized the treatment of chronic
myelogenous leukemia and gastrointestinal stromal cancer
(GIST) [4, 5].
Thus, the patient commenced Glivec (Novartis,
Switzerland) 400 mg/day in October 2008. Clinical symptoms
declined within 10 days after initiation of imatinib, and except
for slight stool disorders, no adverse effects were noted during
treatment. Repeated CT scan in January and March 2009
(Figure 1) revealed a progressive and substantial regression of
the tumor mass and durable remission. To date, 8 months after
initiation of imatinib, remission persists and no progression of
disease is noted.
Previous studies have shown that uterine sarcomas rarely
express KIT or PDGFR-b to any determinant degree but
express PDGFR-a protein at high intensity [6, 7]. The case
described herein might therefore be exceptional, but, analogous
to GIST, KIT and PDGFR are homologous and it is tempting to
speculate that downstream signaling molecules might be
targeted.
In GIST, treatment with imatinib is active independent of the
immunohistochemical (IHC) presence or expression level of
KIT [8] as, counterintuitively, IHC KIT-negative or -positive
GIST share similar morphologic, cytogenetic and molecular
features. Wild-type GIST and KIT, but predominantly PDGFR-
a mutations, have been found in IHC KIT-negative GIST
activating the same downstream oncogenic molecules [9].
However, analysis of exons 12 and 18 of the kinase receptor
in our patient (methodology as was described previously [6]),
did not reveal mutational status and thus does not entirely
explain for the responsiveness toward tyrosine kinase
inhibition.
Given the paucity of effective chemotherapeutic regimens
but in turn novel molecular targets in uterine sarcomas, here
we demonstrate for the first time that rational, i.e. based on
IHC detection, PDGFR-b and -a inhibition with imatinib in
this relapsed uterine ESS resulted in a durable remission.
Figure 1. Repeated computed tomography scan conducted at the initiation of imatinib therapy (14 · 9 cm2), 4 and 6 months thereafter, respectively,
demonstrating the substantial regression of the endometroid uterine sarcoma (4 · 3 cm2).
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Our findings indicate a role for PDGFR signaling in ESS
development, with PDGFR and its downstream signaling
molecules representing a novel therapeutic target in ESS.
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